FolioLanternBeta
ARTVArtiva Biotherapeutics, Inc.

Fred Aslan

Chief Executive Officer, Director at Artiva Biotherapeutics, Inc., as of Oct 7, 2026Sold $2.0M of stock in the past 12 months: 31% under a disclosed plan and 69% to cover taxes.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
1.52M
shares held after the latest filing, Artiva Biotherapeutics, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
233K
shares sold, past 12 months
8
days with sales
$690K
largest single day, Sep 3, 2026
1
company filed for

Share of stake sold at Artiva Biotherapeutics, Inc. is not shown: most of their shares vested during the period, so a percentage would mislead. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled
Oct 2025: $153K under a disclosed planOctNov 2025: $22K under a disclosed planNovDec 2025: $19K under a disclosed planDecJanFebMarAprMay 2026: $244K to cover taxesMayJunJulAugSep 2026: $256K under a disclosed planSep 2026: $690K to cover taxes$946KSepOct 2026: $169K under a disclosed planOct 2026: $422K to cover taxesOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Artiva Biotherapeutics, Inc. (ARTV)Chief Executive Officer, DirectorJul 18, 2024Oct 7, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.